<DOC>
	<DOC>NCT01155388</DOC>
	<brief_summary>To evaluate the efficacy and safety of IV ferumoxytol compared with oral iron for the treatment of pediatric subjects with nondialysis-dependent chronic kidney disease.</brief_summary>
	<brief_title>A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-Dependent Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include: 1. Males or females 6 months to &lt;18 years of age 2. Nondialysis dependent CKD, including kidney transplant recipients 3. Has IDA defined as: a) hemoglobin &lt;11.0 g/dL and b) TSAT &lt;20% 4. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study Key Exclusion Criteria include: 1. History of allergy to either oral or intravenous (IV) iron 2. Allergy to two or more classes of drugs 3. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, within 3 months postpartum, or have a positive serum/urine pregnancy test 4. Hemoglobin â‰¤7.0 g/dL 5. Serum ferritin &gt;600 ng/mL</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Feraheme</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>CKD</keyword>
	<keyword>pediatric</keyword>
	<keyword>nondialysis-dependent</keyword>
	<keyword>The treatment of iron deficiency anemia in pediatric subjects with nondialysis dependent chronic kidney disease</keyword>
</DOC>